| · Female patients aged 18 or older |
· Women in end-of-life care, palliative, or hospice |
| · Diagnosed with early-stage (0-III) breast cancer (included if < 1% of stage IV) |
· Qualitative studies, clinical trial protocol |
| · Estrogen or Progesterone receptor positive |
· Non-English language |
| · Primary breast cancer treatment completed |
· No peer-reviewed article |
| · Being prescribed tamoxifen or an aromatase inhibitor (i.e., anastrozole, letrozole, exemestane), in a clinical practice setting |
|
| · Randomized controlled trials, prospective or retrospective cohort, cross-sectional study design |
|
